or Try an Advanced Search...

    Technical Analysis for BDTX - Black Diamond Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 2.43 -4.71% -0.12
    BDTX closed down 4.71 percent on Wednesday, November 20, 2024, on 35 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical BDTX trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    MACD Bearish Signal Line Cross Bearish -4.71%
    NR7 Range Contraction -4.71%
    NR7-2 Range Contraction -4.71%
    Lower Bollinger Band Walk Weakness -4.71%
    Wide Bands Range Expansion -4.71%
    Lower Bollinger Band Touch Weakness -4.71%
    Older End-of-Day Signals for BDTX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 18 hours ago
    Possible NR7 about 18 hours ago
    Lower Bollinger Band Support about 22 hours ago
    Down 5% about 22 hours ago
    Down 3% about 22 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    BDTX Chart by TradingView
    Basic chart:

    Profile

    Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Cancer Treatment Enzymes Diamond Epidermal Growth Factor Receptor Tyrosine Kinase Receptors Genetic Diseases Oncogenes Therapies For Cancer Protein Kinase Rare Genetic Disease Rare Genetic Diseases Black Diamond Kinase

    Is BDTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 5 Black Diamond: Q3 Earnings Snapshot
    Nov 5 Black Diamond Therapeutics GAAP EPS of -$0.28 beats by $0.09
    Nov 5 Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks
    Nov 5 Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    Nov 1 Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    Oct 8 Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
    Oct 7 Black Diamond CFO departs as part of restructuring, job cuts
    Oct 7 Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
    Sep 23 Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
    Sep 23 Black Diamond reports encouraging Phase 2 data for BDTX-1535
    See more BDTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.66
    52 Week Low 2.155
    Average Volume 1,375,341
    200-Day Moving Average 4.86
    50-Day Moving Average 3.63
    20-Day Moving Average 2.95
    10-Day Moving Average 2.92
    Average True Range 0.24
    RSI (14) 29.58
    ADX 29.52
    +DI 11.76
    -DI 31.84
    Chandelier Exit (Long, 3 ATRs) 2.73
    Chandelier Exit (Short, 3 ATRs) 3.09
    Upper Bollinger Bands 3.50
    Lower Bollinger Band 2.40
    Percent B (%b) 0.03
    BandWidth 37.15
    MACD Line -0.27
    MACD Signal Line -0.25
    MACD Histogram -0.0245
    Fundamentals Value
    Market Cap 125.47 Million
    Num Shares 51.6 Million
    EPS -2.13
    Price-to-Earnings (P/E) Ratio -1.14
    Price-to-Sales 0.00
    Price-to-Book 1.63
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.70
    Resistance 3 (R3) 2.71 2.64 2.66
    Resistance 2 (R2) 2.64 2.57 2.63 2.64
    Resistance 1 (R1) 2.53 2.53 2.50 2.52 2.62
    Pivot Point 2.46 2.46 2.44 2.45 2.46
    Support 1 (S1) 2.35 2.39 2.32 2.34 2.24
    Support 2 (S2) 2.28 2.35 2.27 2.22
    Support 3 (S3) 2.17 2.28 2.21
    Support 4 (S4) 2.16